Stage 3 Mesothelioma: 3A vs 3B, Symptoms & Treatment

Stage 3 pleural mesothelioma is an advanced stage of malignant pleural mesothelioma in which the cancer has grown more extensively within the chest and/or reached regional lymph nodes, but distant metastasis has not been identified.

Under the current American Joint Committee on Cancer (AJCC) Version 9 TNM staging system, Stage 3 is divided into Stage IIIA and Stage IIIB. This distinction matters because the extent of the tumor, lymph-node involvement, overall health, and whether the disease is considered resectable can influence treatment planning.

A diagnosis of Stage 3 does not indicate that all treatment options have been exhausted. Selected patients with Stage IIIA disease may be considered for surgery within a multimodality treatment approach. Conversely, systemic therapies such as immunotherapy and chemotherapy are key options for unresectable disease. A multidisciplinary team with expertise in pleural mesothelioma should conduct treatment planning.

Stage 3 Mesothelioma at a Glance

What Does Stage 3 Mesothelioma Mean?

The stage of pleural mesothelioma describes the anatomical extent of the cancer at the time it is assessed. Doctors use three main categories:

• T — Tumor: the extent of the primary pleural tumor.
• N — Nodes: whether cancer has reached regional lymph nodes.
• M — Metastasis: whether cancer has spread to distant sites.

These categories are combined into an overall stage. For Stage 3 pleural mesothelioma, the disease remains M0, meaning distant metastasis has not been identified. The distinction between Stage IIIA and IIIB is based on the T and N categories. See our mesothelioma stages overview for how Stage 3 relates to the full AJCC staging system.

AJCC Version 9 Stage 3 Groups

This Version 9 classification is important because older articles may describe lymph-node involvement differently. Under the current system, N2 disease can still be classified as Stage IIIA. Stage IIIB is defined by a T4 primary tumor, regardless of the regional N category, as long as distant metastasis is absent.

Stage 3A vs Stage 3B Mesothelioma

Stage IIIA and Stage IIIB are both advanced forms of pleural mesothelioma, but they are not interchangeable.

Stage 3A Mesothelioma

Stage IIIA can result from several combinations of tumor extent and lymph-node involvement. It includes:

• T2 disease with N1 lymph-node involvement;
• T3 disease with N0 or N1 nodes; or
• T1, T2, or T3 disease with N2 lymph-node involvement.

In Version 9, N1 generally describes regional lymph nodes on the same side as the primary tumor, while N2 includes contralateral mediastinal lymph nodes and supraclavicular lymph nodes on either side.

Some people with Stage IIIA mesothelioma may still have disease considered potentially resectable. However, the stage alone does not determine whether surgery is appropriate.

Stage 3B Mesothelioma

Stage IIIB corresponds to: T4, any N, M0.

T4 means the primary tumor has extended into structures in a way that generally makes complete surgical removal unrealistic. Examples can include extensive invasion involving structures such as the chest-wall bone, mediastinal organs, opposite pleura, or tumor extending through the diaphragm or pericardium. The cancer can have any regional lymph-node status, but there is still no distant metastasis.

Stage Does Not Equal Resectability

One of the most important concepts to understand about Stage 3 mesothelioma is that stage and resectability are related but not identical.

Resectability asks a different question: can the visible tumor reasonably be removed with surgery while maintaining an acceptable balance between potential benefit and risk?

The American Cancer Society notes that some Stage 3 pleural mesotheliomas may still be considered resectable, although there are important exceptions. Factors influencing this assessment include tumor location and extent, histologic subtype, lymph-node involvement, and whether the person is medically fit enough for major thoracic surgery.

Therefore, evaluation at a specialized mesothelioma center is recommended before determining the feasibility of specific treatment options. Our find a specialist guide can help with that search.

What Are the Symptoms of Stage 3 Mesothelioma?

No symptom proves a person has Stage 3 rather than another stage. Staging is determined through imaging, pathology, and other clinical information, not symptoms alone.

However, as pleural tumors become more extensive, symptoms may become more noticeable. Possible symptoms include:

• shortness of breath;
• chest pain or pressure;
• persistent cough;
• fatigue;
• reduced exercise tolerance;
• loss of appetite;
• unintended weight loss;
• pleural effusion, or fluid around the lung;
• discomfort related to chest-wall involvement.

Symptoms vary substantially from one person to another. Their severity does not always correspond directly to cancer stage. A person with substantial disease can sometimes have relatively modest symptoms, while another person with less extensive disease may experience significant breathlessness or pain.

New or worsening symptoms should be reported to the treating medical team for assessment, rather than being used to estimate cancer stage independently. Our symptoms guide covers the broader range of possible signs.

How Is Stage 3 Mesothelioma Diagnosed?

A diagnosis of Stage 3 pleural mesothelioma generally involves two separate steps: confirming that the tumor is mesothelioma, and determining how far the disease has spread. Our diagnosis guide and tests and biopsy guide cover this process in more detail.

Biopsy and Pathology

A tissue biopsy is typically needed to establish a definitive diagnosis. The pathology assessment helps determine whether malignant mesothelioma is present and identifies the histologic subtype, such as:

• epithelioid;
• biphasic;
• sarcomatoid.

Histology is important because tumor biology can influence prognosis and treatment planning.

CT Imaging

Contrast-enhanced CT imaging can help assess pleural tumor distribution, pleural thickness, involvement of neighboring structures, lymph nodes, pleural effusion, and possible disease elsewhere in the chest. AJCC Version 9 also incorporates quantitative assessment of pleural thickness, known as Psum, into the T classification. Our imaging tests guide covers CT, PET, and MRI in more detail.

PET/CT

PET/CT may provide additional information about metabolically active disease and can help identify suspicious lymph nodes or possible disease outside the primary pleural region. An abnormal PET finding does not by itself prove mesothelioma spread; biopsy or additional assessment may sometimes be needed.

MRI

MRI can be useful in selected patients when doctors need additional detail about local tumor extension, particularly around structures such as the diaphragm, chest wall, or mediastinum.

Lymph-Node Evaluation

Because lymph-node status affects staging, additional sampling may sometimes be recommended. Depending on the clinical situation, assessment can involve techniques such as endobronchial ultrasound-guided sampling, endoscopic ultrasound-guided sampling, mediastinoscopy, or surgical lymph-node sampling. Not all patients require every diagnostic test; the staging workup should be tailored to the individual clinical scenario.

Clinical Stage vs Pathologic Stage

A person may initially receive a clinical stage based on imaging, biopsy results, examination, and other tests. If surgery is performed, doctors may obtain additional information directly from the chest and from surgically removed tissue. This can produce a pathologic stage. The pathologic stage can sometimes differ from the clinical stage because surgery may reveal disease that was not clearly visible on preoperative imaging.

How Is Stage 3 Mesothelioma Treated?

There is no single treatment plan that is appropriate for every person with Stage 3 mesothelioma. Treatment depends on factors such as Stage IIIA versus IIIB, whether the tumor is resectable, histologic subtype, lymph-node involvement, previous treatment, age and overall health, lung and heart function, symptoms, treatment goals, and patient preferences.

A multidisciplinary mesothelioma team may include thoracic surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, palliative-care specialists, and other professionals. Our treatment guide covers these approaches across all stages.

Surgery for Stage 3 Mesothelioma

Surgical cytoreduction is not routinely recommended for all patients with Stage 3 disease. It may be considered for highly selected patients with favorable features after comprehensive staging and multidisciplinary review, particularly some people with Stage IIIA disease.

When surgical cytoreduction is appropriate, lung-sparing approaches such as pleurectomy/decortication are generally favored when feasible. Extrapleural pneumonectomy is reserved for highly selected patients at experienced mesothelioma centers.

Surgery for mesothelioma is complex and is generally considered as part of a broader multimodality strategy rather than as an isolated treatment. Not every Stage IIIA tumor is surgically removable, and being technically resectable does not automatically mean surgery offers the best risk-benefit balance for a particular patient.

Stage IIIB disease is generally considered unresectable because the T4 tumor has invaded structures that prevent complete macroscopic resection.

Consultation at a high-volume mesothelioma center is recommended when surgical intervention is under consideration.

Immunotherapy

Immune checkpoint inhibitors have become an important part of treatment for unresectable malignant pleural mesothelioma.

Nivolumab Plus Ipilimumab — The FDA has approved nivolumab plus ipilimumab as first-line treatment for adults with unresectable malignant pleural mesothelioma. These medications target immune checkpoints and are intended to help the immune system recognize and attack cancer cells more effectively. Whether this combination is appropriate depends on the person’s overall clinical situation and treatment history.

Chemotherapy

Platinum-based chemotherapy combined with pemetrexed remains an important systemic treatment option for pleural mesothelioma. A platinum drug may include cisplatin or carboplatin. Chemotherapy can be used alone in selected situations or incorporated into a broader treatment strategy. The NCI lists systemic treatment among the principal approaches used for advanced mesothelioma.

Pembrolizumab Plus Chemotherapy — In September 2024, the FDA approved pembrolizumab combined with pemetrexed and platinum chemotherapy as first-line treatment for adults with unresectable advanced or metastatic malignant pleural mesothelioma. The approval was based on the KEYNOTE-483 trial, which showed an improvement in overall survival for the pembrolizumab-plus-chemotherapy group compared with chemotherapy alone. This does not mean that pembrolizumab plus chemotherapy is automatically the preferred treatment for every person with Stage 3 disease. The choice among available systemic approaches depends on tumor characteristics, medical history, contraindications, previous treatment, expected toxicity, and patient preferences.

Radiation Therapy

Radiation therapy can have several possible roles in pleural mesothelioma care. Depending on the clinical situation, it may be considered as part of selected multimodality approaches, for local disease control, to relieve cancer-related pain, or to manage symptoms caused by a specific tumor site. Radiation planning in pleural mesothelioma can be technically complex because of the proximity of the lungs, heart, esophagus, spinal cord, and other critical structures.

Multimodality Treatment

Because pleural mesothelioma often grows along pleural surfaces rather than forming a single well-defined mass, treatment frequently involves more than one modality. For selected patients, a plan might incorporate different combinations of systemic therapy, surgery, and radiation therapy. The sequence and combination should be individualized. The term “multimodality treatment” does not imply that all patients should undergo every available therapy — the potential benefit of an intensive strategy must always be weighed against its risks.

Palliative and Supportive Care

Palliative care is distinct from hospice care and does not signify discontinuation of cancer treatment. Palliative care focuses on reducing symptoms, preserving function, and improving quality of life, and it can be provided at the same time as active anticancer treatment.

For pleural mesothelioma, supportive interventions may address problems such as breathlessness, pleural fluid accumulation, chest pain, fatigue, appetite problems, anxiety or distress, and sleep difficulties. Management of recurrent pleural effusion may include drainage procedures or pleurodesis in appropriate cases. Radiation therapy can also sometimes be used to relieve localized cancer-related pain. The NCI includes symptom-directed and palliative treatment among the options for advanced mesothelioma.

Clinical Trials for Stage 3 Mesothelioma

Clinical trials are an important consideration in a rare cancer such as mesothelioma. Trials may evaluate new immunotherapy combinations, different sequences of systemic therapy, novel targeted approaches, new radiation strategies, perioperative treatments, and biomarkers that may help select therapy.

Eligibility depends on factors such as stage, histology, previous treatments, performance status, organ function, and specific trial criteria. A mesothelioma specialist can assist in determining eligibility for appropriate clinical trials.

Stage 3 Mesothelioma Prognosis

Stage is important, but it is only one part of prognosis. Outcome can also be influenced by histologic subtype, performance status, age and general health, extent of tumor involvement, lymph-node status, whether disease can be resected, response to treatment, laboratory findings, and other medical conditions. The American Cancer Society identifies factors such as functional status and epithelioid histology among variables associated with prognosis in addition to stage. Our prognosis guide discusses these factors across all stages.

How Long Can Someone Live With Stage 3 Mesothelioma?

There is no single reliable life-expectancy number that applies to every person with Stage 3 mesothelioma. Published studies involve different staging editions, patient populations, histologic subtypes, treatments, surgical selection criteria, and periods of diagnosis. As a result, providing a single “Stage 3 life expectancy” figure may be misleading.

Population survival statistics also cannot predict how long a person will live. For example, commonly cited SEER survival categories use localized, regional, and distant disease, which are not identical to AJCC Stage I, II, III, and IV. Those categories should not simply be relabeled as “Stage 3 survival.”

A specialist with knowledge of the patient’s imaging, pathology, overall health, and treatment response can offer a more individualized and meaningful prognosis discussion.

Can Stage 3 Mesothelioma Be Cured?

Mesothelioma remains a difficult cancer to cure. For most people with advanced pleural mesothelioma, treatment aims to control the disease, prolong survival when possible, reduce symptoms, and maintain quality of life. However, Stage 3 covers a heterogeneous group of patients. Some carefully selected people with potentially resectable Stage IIIA disease may undergo intensive multimodality treatment. It is more appropriate to discuss treatment goals and realistic outcomes on an individual basis, rather than assuming uniform prognosis for all Stage 3 diagnoses.

Is Stage 3 Mesothelioma Terminal?

A Stage 3 diagnosis is serious, but the term terminal does not accurately describe every person at the time of diagnosis. Stage 3 means the cancer is advanced locally and/or regionally but has not met the criteria for distant metastatic Stage 4 disease. Patients may still receive active treatment including systemic therapy, symptom-directed treatment, clinical-trial therapy, and, for selected patients, surgery-based approaches. The treating oncology team is best equipped to determine whether treatment is intended for disease control, symptom relief, long-term remission, or other specific objectives.

Stage 3 vs Stage 4 Mesothelioma

The most important distinction is distant metastasis.

Stage 4 pleural mesothelioma is defined by M1 disease, regardless of the T or N category. See our Stage 4 mesothelioma guide for more detail.

What to Do After a Stage 3 Diagnosis

A Stage 3 diagnosis can generate many decisions in a short period of time. Useful questions for the oncology team include:

1. Is this Stage IIIA or Stage IIIB under AJCC Version 9?
2. What are my exact T, N, and M categories?
3. Has the pathology been reviewed by a pathologist experienced in mesothelioma?
4. What is my mesothelioma histologic subtype?
5. Is additional lymph-node staging needed?
6. Is the disease considered resectable or unresectable?
7. Should I obtain an opinion from a mesothelioma treatment center?
8. What systemic treatment options are appropriate for me?
9. Is surgery worth considering in my case?
10. Are there clinical trials for which I may qualify?
11. How will symptoms such as breathlessness, pain, or pleural effusion be managed?
12. What are the goals, expected benefits, and major risks of each treatment option?

Obtaining a second opinion is particularly valuable in cases of uncertainty regarding resectability, pathology, or optimal treatment sequencing. Our find a specialist guide can help locate an experienced mesothelioma center.

Frequently Asked Questions

What is Stage 3 mesothelioma?

Stage 3 pleural mesothelioma is advanced disease that has spread more extensively within the chest and/or to regional lymph nodes but has not spread to distant sites. Under AJCC Version 9, it is divided into Stage IIIA and IIIB.

What is the difference between Stage 3A and Stage 3B mesothelioma?

Stage IIIA includes several combinations of T1–T3 tumors and regional lymph-node involvement. Stage IIIB is T4, any N, M0. Stage IIIB therefore reflects extensive local tumor invasion rather than simply “more lymph-node spread.”

Can Stage 3 mesothelioma be operated on?

Some people with Stage IIIA disease may be candidates for surgery, but many are not. Resectability depends on anatomy, tumor biology, lymph nodes, general health, and evaluation by an experienced multidisciplinary team. Stage IIIB/T4 disease is generally considered unresectable.

Has Stage 3 mesothelioma spread to distant organs?

No. Stage 3 pleural mesothelioma remains M0. Evidence of distant metastasis would classify the disease as Stage 4 under AJCC Version 9.

What treatments are available for Stage 3 mesothelioma?

Depending on the individual case, treatment may include immunotherapy, platinum-pemetrexed chemotherapy, pembrolizumab with platinum-pemetrexed chemotherapy for eligible unresectable disease, surgery in carefully selected patients, radiation therapy, clinical trials, and palliative/supportive care.

Does Stage 3 automatically mean hospice?

No. Stage 3 patients may still receive active anticancer treatment. Palliative care can also be provided alongside treatment to control symptoms and improve quality of life.

Should I get a second opinion?

A second opinion may be particularly useful for a rare cancer such as mesothelioma, especially when surgery, clinical-trial participation, pathology interpretation, or the choice between systemic treatment strategies is being considered.

Medical References

1. American Joint Committee on Cancer. Malignant Pleural Mesothelioma. AJCC Cancer Staging System, Version 9. American College of Surgeons; 2024.
2. American Cancer Society. Stages of Mesothelioma. cancer.org, last revised February 3, 2026.
3. Kindler HL, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Update. Journal of Clinical Oncology. 2025;43:1006–1038. doi:10.1200/JCO-24-02425.
4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Mesothelioma: Pleural. Version 2.2026.
5. National Cancer Institute. Mesothelioma Treatment. cancer.gov, updated May 16, 2025.
6. U.S. Food and Drug Administration. FDA Approves Pembrolizumab With Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma. September 17, 2024.
7. U.S. Food and Drug Administration. Nivolumab plus ipilimumab prescribing information for unresectable malignant pleural mesothelioma.

Editorial and Medical Review Information